Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vici, Patrizia, Pizzuti, Laura, Natoli, Clara, Moscetti, Luca, Mentuccia, Lucia, Vaccaro, Angela, Sergi, Domenico, Di Lauro, Luigi, Trenta, Patrizia, Seminara, Patrizia, Santini, Daniele, Iezzi, Laura, Tinari, Nicola, Bertolini, Ilaria, Sini, Valentina, Mottolese, Marcella, Giannarelli, Diana, Giotta, Francesco, Maugeri-Saccà, Marcello, Barba, Maddalena, Marchetti, Paolo, Michelotti, Andrea, Sperduti, Isabella, Gamucci, Teresa
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2014
Konular:
Clinical Trial
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174332/
https://ncbi.nlm.nih.gov/pubmed/25234842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3133-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller